Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Gadolinium DTPA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1988

Comparative pharmacokinetics of gadolinium DTPA and gadolinium chloride.

An intravenous injection of 153Gd-labeled gadolinium-DTPA or gadolinium chloride was given to 60 rats, which were killed either 15, 40, 120, 300, 900, or 3600 seconds later. Tissue concentrations of gadolinium in the blood, liver, spleen, stomach, pancreas, renal cortex, renal medulla, lungs, heart, adrenals, gluteal muscle, fat, skin, thymus, brain, thyroid, and parathyroids were measured. Five animals were killed at each time interval with gadolinium-DTPA, and at each of the latter four time intervals (15 and 40 seconds excluded) with gadolinium chloride. The pharmacokinetics of gadolinium-DTPA and chloride differ markedly in terms of tissue concentration, distribution volumes, and the time course of these parameters. Gadolinium, when injected as a chloride, evidently forms insoluble carbonate and phosphate precipitates in the blood, which are taken up by the reticuloendothelial system. The distribution of gadolinium-DTPA on dynamic MRI should closely parallel the distribution of iodinated contrast media on dynamic computed tomography.

Animals↗
PubMed1991

Magnetic resonance imaging of the pancreas with gadolinium-DTPA.

Gadolinium (Gd)-DTPA was evaluated as a contrast agent for magnetic resonance (MR) imaging of the pancreas at 1.5T. Twenty-five patients were imaged with identical gradient-echo (GE) (TR 47, TE 13, 80 degree pulse angle) and spin-echo (SE) (TR 300, TE 15) MR sequences prior to and following an intravenous bolus of 0.1 mmol/kg Gd-DTPA. Marked pancreatic enhancement was demonstrated on dynamic sequential breath-hold GE images obtained immediately following the Gd-DTPA bolus (116% mean enhancement over pre-Gd-DTPA images). Enhancement decreased but persisted on the SE images obtained approximately 5 and 15 min following the Gd-DTPA bolus (65 and 60% mean enhancement, respectively). Five of the patients had a pancreatic mass. In these five patients, the enhancement of pancreatic tissue resulted in improved conspicuity of the mass. These initial results suggest that pancreatic enhancement occurs following an intravenous bolus of Gd-DTPA and has the potential to improve MR visualization of pancreatic masses.

Adenocarcinoma↗
PubMed1994

Dynamic contrast-enhanced MR imaging of the upper abdomen: enhancement properties of gadobutrol, gadolinium-DTPA-polylysine, and gadolinium-DTPA-cascade-polymer.

The enhancement properties of gadobutrol (40 and 80 mumol/kg body weight, 550 daltons), gadolinium-DTPA-polylysine (20 mumol/kg body weight, 53,000 daltons) and gadolinium-DTPA-cascade-polymer (20 mumol/kg body weight, < 30,000 Daltons) were investigated in abdominal MR imaging using a pig model (n = 24). Signal intensities before and after contrast media application were assessed using a fast single slice FLASH sequence. Measurements were made every 4 s within the first 116 s, every minute between 4 and 10 min and after 15, 20, 30, 40, 50, 60, 90, and 120 min after contrast media injection. Injection of gadobutrol resulted in typical signal intensity curves characterizing it as an extracellular agent similar to gadopentetate dimeglumine. Significant enhancement was found in all tissues except the trunk muscles when the lower dose was administered. Gadolinium-DTPA-polylysine injection resulted also in significant enhancement of the liver, the pancreas, and the renal cortex, but not of the trunk muscle, reflecting its blood pool properties known also from other macromolecular contrast agents. The signal intensity curves obtained after gadolinium-DTPA-cascade-polymer injection were similar to those obtained after polylysine injection, stressing the blood pool character of this new type of blood pool agent.

Abdomen↗
PubMed1995

Comparison of gadolinium-DTPA and polylysine-gadolinium-DTPA--enhanced magnetic resonance imaging of hepatocarcinoma in the rat.

RATIONALE AND OBJECTIVES: To compare the magnetic resonance (MR) imaging characteristics of gadolinium-DTPA (Gd-DTPA), a low-molecular-weight contrast agent, and polylysine-Gd-DTPA, a macromolecular contrast agent, in two types of hepatocarcinomas (HCC) in the rat. METHODS: T1-weighted spin-echo images were obtained in 13 rats with chemically induced HCC and 26 rats with Novikoff HCC before and 3 minutes to 60 hours after administration of either Gd-DTPA or polylysine-Gd-DTPA. RESULTS: Three minutes after polylysine-Gd-DTPA administration, the tumor-to-liver contrast of the two types of HCC increased significantly (positive contrast for chemically induced HCC and negative contrast for Novikoff HCC). At 30 minutes and 60 hours, the tumor-to-liver contrast remained above baseline values in chemically induced HCC and returned progressively to baseline values in Novikoff HCC. No significant increase in tumor-to-liver contrast was observed after Gd-DTPA administration. CONCLUSIONS: These results suggest that polylysine-Gd-DTPA provides a higher and more prolonged increase in tumor-to-liver contrast than Gd-DTPA.

Angiography↗
PubMed1996

Comparison of gadolinium-DTPA and macromolecular gadolinium-DTPA-polylysine for contrast-enhanced pulmonary time-of-flight magnetic resonance angiography.

RATIONALE AND OBJECTIVES: The authors investigated the enhancing effect of low-dose administration of the macromolecular, paramagnetic contrast medium gadolinium (Gd)-DTPA-polylysine (average molecular weight, 40,000-50,000 dalton [D]) compared with Gd-DTPA (molecular weight, 547 D) in time-of-flight magnetic resonance angiography of unilaterally damaged sheep lungs. MATERIALS AND METHODS: Thirteen heart-lung preparations were examined in the head coil of a 1.5-tesla imager (Magnetom SP, Siemens, Erlangen, Germany). The authors performed time-of-flight angiograms (coronal; repetition time, 35 mseconds; echo time, 6 mseconds; 20 degrees flip angle; pixel size 1.0 x 1.0 x 1.5 mm3) before and after application of the contrast agents. Gadolinium-DTPA-polylysine was used in a dose of 0.027 mmol/kg body weight while Gd-DTPA was injected in variable doses. RESULTS: After Gd-DTPA-polylysine, signal intensity increased by 118% in pulmonary arteries in healthy lungs and by 121% in damaged lungs (P < 0.001). In addition, the contrast-to-noise ratio measured between pulmonary arteries and perivascular parenchyma increased significantly (P < 0.01). On three-dimensional angiograms, two more generations of vascular branches could be detected. A dose of Gd-DTPA 6.1 times higher than the Gd-DTPA-polylysine dose was necessary to obtain the same contrast enhancing effect as Gd-DTPA-polylysine in healthy lungs. In damaged lungs, none of the administered doses of Gd-DTPA reached the average contrast enhancement of Gd-DTPA-polylysine. CONCLUSIONS: The authors' measurements demonstrate significant improvement of time-of-flight angiograms by low-dose administration of Gd-DTPA-polylysine.

Animals↗
PubMed1990

Biodistribution and clearance of liposomal gadolinium-DTPA.

Gadolinium-DTPA (Gd-DTPA) liposomes have been studied previously as liver contrast agents and have been shown to improve the detection of hepatic metastases in rats. We synthesized 100-nm and 50-nm liposomes that encapsulated Gd-DTPA and did biodistribution and clearance studies in rats. Parallel magnetic resonance imaging (MRI) studies were also done. Biodistribution showed a prolonged blood pool phase for Gd-DTPA liposomes with a blood pool half-life of approximately 4 hours for the 100-nm liposomes. The highest uptake per gram of tissue was achieved by the spleen. Clearance of gadolinium from the liver and spleen showed a half-life of 3 to 4 days. The smaller 50-nm Gd-DTPA liposomes resulted in a longer blood pool phase and a higher delivery of gadolinium to the liver, bone marrow, and spleen. Imaging studies after intravenous (IV) administration of liposomal Gd-DTPA showed organ enhancement that paralleled the data on biodistribution studies, with appreciable hepatic enhancement at doses as low as 0.025 mm/kg of liposomal Gd-DTPA.

Animals↗
PubMed1985

Tissue distribution and magnetic resonance spin lattice relaxation effects of gadolinium-DTPA.

Gadolinium-DTPA complex (Gd-DTPA) is a potential clinical magnetic resonance (MR) contrast agent that enhances images primarily by decreasing spin-lattice relaxation time (T1) in tissues in which it localizes. This study was designed to determine the immediate tissue distribution of intravenously administered Gd-DTPA in selected organs of interest as a function of administered dose and tissue Gd-DTPA concentration. An intravenous bolus of Gd-DTPA with a tracer quantity of Gd-153 was administered to three groups of rabbits at the following doses: 0.01 mM/kg (n = 6); 0.05 mM/kg (n = 6); 0.10 mM/kg (n = 6). A control group received sham injections. Five minutes after Gd-DTPA was administered, all animals were killed; samples of serum, lung, heart, kidney, liver, and spleen were analyzed in a 0.25 T MR spectrometer to measure T1, and then in a gamma well counter to determine tissue concentration of Gd-DTPA. Tissue distribution (per cent dose/tissue weight in g) at five minutes after injection was proportionally constant over the range of doses given. Tissue concentration varied linearly with injected dose (r greater than 0.98 for all tissues). Relaxation rate (1/T1) varied linearly with injected dose and with tissue Gd-DTPA concentration (r greater than 0.97 for all tissues). The order of tissue relaxation rate response to a given dose was: kidney greater than serum greater than lung greater than heart greater than liver greater than spleen. We conclude that because of its extracellular distribution and linear relaxation rate versus concentration relationship, Gd-DTPA enhancement in MR images may be a good marker of relative organ perfusion.

Animals↗
PubMed1984

Acute myocardial ischemia: magnetic resonance contrast enhancement with gadolinium-DTPA.

Gadolinium-DTPA (Gd-DTPA) was used to improve the diagnostic utility of magnetic resonance (MR) in detecting early ischemia, before the onset of infarction. Following one minute of left anterior descending coronary artery occlusion, 9 dogs were intravenously injected with either 0.5 mM/kg of Gd-DTPA (6 dogs) or normal saline (3 dogs). One more minute was allowed for perfusion of injectate prior to cardiectomy and MR imaging of the ex situ heart. There was no visible difference in intensity or alterations in magnetic relaxation times between normal and ischemic myocardium in the control (saline-injected) animals. The Gd-DTPA-injected dogs had a well-defined segment of high intensity representing the ischemic myocardium in the anterior wall of the left ventricle, due to significant T2 relaxation rate enhancement in the adjacent normal myocardium. Both T1 and T2 were significantly (p less than 0.01) shortened in the normal myocardium of the Gd-DTPA animals, but relatively greater T2 relaxation rate enhancement resulted in reduced intensity of normal myocardium, thus increasing contrast with ischemic myocardium. As a result of the significant shortening of T1 and T2 in the normal myocardium relative to the ischemic myocardium, improved delineation of the ischemic segment could be obtained using calculated T1 and T2 images. It is concluded that Gd-DTPA has the potential to expand the sensitivity and diagnostic utility of MR in the study of occlusive coronary artery disease.

Animals↗
PubMed1984

Contrast-enhanced NMR imaging: animal studies using gadolinium-DTPA complex.

Gadolinium (Gd)-DTPA complex was assessed as a nuclear magnetic resonance (NMR) contrast-enhancing agent by experimentally imaging normal and diseased animals. After intravenous injection, Gd-DTPA, a strongly paramagnetic complex by virtue of unpaired electrons, was rapidly excreted into the urine of rats, producing an easily observable contrast enhancement on NMR images in kidney parenchyma and urine. Spin-echo intensity of urine within the renal pelvis increased from 2263 to 4414 units; intensity of renal parenchyma increased from 2901 to 3893 after administration of 0.1 mmol/kg Gd-DTPA. Sterile soft-tissue abscesses demonstrated an obvious rim pattern of enhancement. A focus of radiation-induced brain damage in a canine model was only faintly detectable on spin-echo NMR images before contrast administration; after 0.5 mmol/kg Gd-DTPA administration, the lesion intensity increased from 3867 to 5590. In comparison, the normal brain with an intact blood-brain barrier remained unchanged in NMR characterization. Gd-DTPA is a promising new NMR contrast enhancer for the clinical assessment of renal function, of inflammatory lesions, and of focal disruption of the blood-brain barrier.

Abscess↗
PubMed1991

An improved method for the preparation of liposomal gadolinium-DTPA. Ionophore-mediated active entrapment of gadolinium.

We have developed an improved method for the production of liposomal gadolinium-DTPA (Gd-DTPA). The ionophore A23187 facilitates the uptake of externally added Gd into the interior aqueous space of a unilamellar lipid vesicle, where it is chelated by passively entrapped DTPA to form the Gd-DTPA chelate in situ. The presence of a pH gradient across the vesicle membrane is not essential for Gd uptake, the extent of which apparently is limited only by the interior concentration of the chelator. Once formed internally, the Gd-DTPA complex is retained within the vesicles for at least several days at room temperature. Biodistribution studies in mice indicate that liposomal Gd-DTPA prepared by this ionophoretic loading procedure exhibits biodistribution and clearance characteristics similar to 153Gd-DTPA-labeled liposomes prepared by means of passive entrapment of the preformed chelate.

Calcimycin↗
PubMed1988

Gadolinium-DTPA in the evaluation of intradural extramedullary spinal disease.

Gadolinium-DTPA was used in MR imaging of the spine to determine the ability of a contrast agent to increase the detection and characterization of disease in the intradural extramedullary space. Although MR imaging, especially with recent technological improvements, has been shown to be at least competitive with, and often superior to, myelography and postmyelography CT in the study of intramedullary and extradural disease, its use in the assessment of intradural extramedullary disease has been questioned. We selected 12 patients with intradural extramedullary disease as demonstrated by positive CSF cytology and/or myelographic findings and performed MR examinations on them before and after administering gadolinium-DTPA (0.1 mmol/kg). Gadolinium-DTPA was extremely effective in depicting intradural extramedullary disease of the spine. Small nodules of 3 mm, virtually invisible on noncontrast MR scans, enhanced strongly and were easily detected. In addition, leptomeningeal spread of tumor along nerve roots was also visualized, sometimes more readily than by myelography and postmyelography CT. The remarkable sensitivity of gadolinium-DTPA to intradural extramedullary disease assures its role in future MR examinations of the spine.

Adult↗
PubMed1999

[Acute myocardial infarct studied by magnetic resonance with gadolinium-DTPA contrast compared to echocardiography].

INTRODUCTION AND OBJECTIVES: Gadolinium-DTPA used as a contrast agent in magnetic resonance imaging allows the detection and quantification of the necrotic area in acute myocardial infarction. The aim of the present study is to assess the value of this method for the diagnosis of myocardial infarction in comparison with clinical and echocardiographic data. METHODS: Contrast magnetic resonance imaging and echocardiographic studies were performed on 16 patients during the first week after admission for acute myocardial infarction. Necrotic and total myocardial mass were calculated from magnetic resonance images and this was compared to the extension of the myocardial infarction assessed by electrocardiography and the peak level of total creatinine-phosphokinase serum enzyme. The number and localization of myocardial segments showing contrast uptake was related to segments with contractile abnormalities at the echocardiographic exam. RESULTS: The mean value of the mass of myocardial necrosis calculated from the total area of gadolinium-DTPA uptake in each patient was 25 g (range: 2-67 g), corresponding to 17% of the total myocardial mass (range: 1-45%). This value correlated with the peak serum level of total creatinine-phosphokinase enzyme (r = 0.714; p < 0.003) and with the number of Q waves present at the electrocardiogram (r = 0.69; p < 0.005). A very good agreement between the location of the myocardial infarction by ECG, echocardiography and magnetic resonance was evidenced, and a satisfactory correlation existed between myocardial segments with gadolinium-DTPA uptake and akinetic echocardiographic segments (kappa = 0.65). CONCLUSIONS: The detection and quantitation of the necrotic area in the acute myocardial infarction with gadolinium-DTPA contrast magnetic resonance shows a good correlation with clinical and echocardiographic data.

Aged↗
PubMed1995

Elimination of gadolinium-DTPA by peritoneal dialysis.

Magnetic resonance urography (MRU) after i.v. injection of gadolinium-DTPA (0.1 mmol/kg bodyweight) was performed in a patient with transplant dysfunction after renal allograft transplantation. Renal replacement therapy was accomplished by means of peritoneal dialysis. Gadolinium-DTPA concentrations in urine and dialysate were measured repeatedly during a 48-h period with inductively coupled plasma atomic emission spectrometry. The total 24-h creatinine clearance was 10.8 ml/min on day 1 and 13.7 ml/min on day 2. The corresponding total gadolinium clearance was 12.8 ml/min and 15.8 ml/min respectively. Gadolinium-DTPA was removed from the body through peritoneal dialysis at a mean clearance rate of 5.13 ml/min. Plasma half-life of gadolinium-DTPA was prolonged to 9 h. No side-effects due to gadolinium-DTPA were noted. MRU provided a better visualization of the morphology of the urinary tract than scintigraphic studies. By measuring the changes of signal intensity, the gadolinium excretion could be calculated.

Adult↗
PubMed1990

Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers.

Gadolinium-DTPA (Gd-DTPA) enhancement seen with magnetic resonance imaging in chronic relapsing experimental allergic encephalomyelitis (CREAE) corresponded with sites of blood-brain barrier breakdown judged by traditional markers in areas of inflammatory demyelination. Duration of Gd-DTPA leakage for individual lesions in CREAE varied from 5 days to more than 5 wks. By contrast, in acute EAE leakage was of shorter duration (always less than 5 days). Selective enhancement was observed in CREAE lesions using Gd-protein markers. Gd-albumin enhancement was not always seen in areas of leakage of the smaller molecular weight compound Gd-DTPA. The addition of immunoglobulin to the gadolinium complex led to enhancement of lesions not seen with Gd-albumin alone. From the similarities between the histology and the patterns of Gd-enhancement in CREAE and multiple sclerosis, it is probable that Gd-enhancement reflects active inflammation (with or without demyelination) in the human disease.

Animals↗
PubMed1996

Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

We studied whether a triple dose of gadolinium-DTPA alone or in combination with delayed scanning increases the sensitivity of brain MRI for detecting enhancing lesions in patients with MS. We obtained T1-weighted brain MRI scans in two sessions for 22 patients with clinically definite MS. In the first session, we obtained one scan 5 to 7 minutes after the injection of 0.1 mmol/kg gadolinium-DTPA (standard dose). In the second session, 6 to 24 hours later, we obtained one scan before the two scans 5 to 7 minutes (for all patients) and one hour (for 11 patients) after the injection of 0.3 mmol/kg gadolinium-DTPA (triple dose). We detected 83 enhancing lesions in 14 patients when the standard dose of gadolinium-DTPA was used. The numbers of enhancing lesions increased to 138 (average increase 66%; p = 0.001) and the numbers of patients with such lesions to 18 (increase 28%) when we used the triple dose of gadolinium-DTPA. In addition, the total area per patient occupied by such lesions was greater (p < 0.0001) and lesion signal intensity higher (p = 0.0001) on the triple-dose scans than the standard-dose scans. There was an increase in the number of large enhancing lesions (p = 0.03) in the scans obtained 1 hour after the injection of the triple dose of gadolinium-DTPA. These data indicate that in patients with MS, a triple dose of gadolinium-DTPA can reveal many more enhancing lesions, which also appear larger. This suggests that the pathologic nature of "active" lesions in MS is heterogeneous, which might have impact on planning clinical trials.

Contrast Media↗
PubMed1987

Magnetic resonance imaging in vascular malformations: studies with and without gadolinium-DTPA.

MRI and gadolinium-DTPA enhanced dynamic MRI increase the information available for and from diagnosis of vascular malformations since it appears possible to obtain nearly specific information about these lesions. Further investigations are needed with fast imaging, flow imaging, and MR substraction angiography to obtain information similar to that obtained by angiography and CT. The value of X-ray CT for the diagnosis of vascular malformations seems to be inferior to MRI since MRI can delineate vessels and flow better and also allows direct multiplanar imaging.

Adult↗
PubMed1992

[Pharmacokinetics of gadolinium-DTPA in chronic renal insufficiency requiring dialysis].

MRT with gadolinium-DTPA (0.1 mmol/kg body weight) was performed in 10 patients with renal insufficiency requiring dialysis and the clearance of gadolinium-DTPA was studied. After 3 dialysis on 3 successive days more than 97% of the initial concentration of gadolinium-DTPA had been eliminated. Average half-life was 1.87 hours. There were no side effects in any of the patients. Close laboratory observation of liver function showed no significant changes during the period of study. No contra-indication for the use of this contrast medium in patients with renal insufficiency requiring dialysis was found during this study.

Adult↗